Overview: Shigella Antigen Rapid TestIntroduction: The Shigella Antigen Rapid Test is a diagnostic tool designed to detect Shigella antigens in stool or rectal swab samples, facilitating the screening of shigellosis. Caused by Shigella bacteria, this acute bacterial dysentery presents with diarrhea, abdominal pain, and severe complications like hemolytic uremic syndrome or sepsis if untreated, particularly in areas with poor sanitation. Per the 2023 World Health Organization guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a critical tool for rapid diagnosis during outbreaks. This rapid diagnostic falls under bacteriology and targets individuals with bloody diarrhea, addressing the challenge of identifying Shigella among other enteric pathogens to guide antibiotic therapy with ciprofloxacin or azithromycin. With morbidity rates elevated due to person-to-person transmission, the test supports public health efforts by enabling early detection, facilitating hygiene interventions, and preventing epidemic spread. Its dual-sample capability enhances its utility.Other Names: Shigella Rapid Test.FDA Status: FDA approved, CLIA certified for bacteriology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Meridian Bioscience, this test advanced Shigella detection, providing a rapid alternative to culture-based methods.Purpose: The test screens for Shigella antigens to guide infection diagnosis, assess disease severity, and inform treatment and prevention strategies.Test Parameters: Presence of Shigella Antigen, detected with high specificity to indicate active infection, typically detectable during the acute phase, peaking within 1-3 days of symptom onset.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report diarrhea, abdominal pain, or recent exposure to ill contacts.Specimen: Stool 5-10 gm, Rectal Swab 1-2 swabs, collected using sterile containers or swabs/transport medium, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antigen integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may denature antigens, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on diarrhea, abdominal pain, fever, or recent travel to endemic areas, as well as any prior Shigella infections or antibiotic use.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including sepsis, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or antibiotic pre-treatment can affect results. Correlation with stool culture or PCR is recommended to confirm findings.Clinical Significance: A positive result indicates Shigella infection, necessitating antibiotic therapy and isolation. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the antigen peak window.Specialist Consultation: Infectious disease specialists or gastroenterologists should be consulted for case management, treatment planning, and coordination with public health authorities.Additional Supporting Tests: Shigella culture, PCR, or serology for confirmation.Test Limitations: The test may produce false negatives in late infection or false positives due to cross-reactivity, requiring a comprehensive diagnostic approach that includes microbiological confirmation.References: WHO Guidelines 2023, Journal of Infectious Diseases 2024, Tropical Medicine and International Health 2025.